

Adult third-line ART update

Michelle
Moorhouse

28 Oct 2018

SAHCS Conference



University of the Witwatersrand

WITS RHI




Disclosures


- Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Mylan, Aspen, Sanofi, Pfizer and Janssen
- Conference sponsorship from BD, Gilead, Janssen, Merck, Cipla and Mylan
- Part of ART optimisation collaborations
- Funding from USAID, Unitaid, SAMRC and study drug donations from ViiV Healthcare and Gilead Sciences for ART optimisation studies




SA has largest ARV programme: > 5 million




SA has largest ARV programme: > 5 million




SA has largest ARV programme: > 5 million




With continued ARV scale up...




Second-line




As more patients fail PI/r regimens...



As more patients fail PI/r regimens...




So how many adults failing PI/r-based ART are accessing third-line ART?




Provincial spread

Cumulative adults on third-line ART* per province




WC numbers do not increase from 2014, as third-line ART
was decentralised to province

As more patients fail PI/r regimens...



The algorithm




The algorithm



Eligible for third line ART?

PI score ≥ 15



DRV/r PLUS 3TC/FTC PLUS
AZT/TDF (lowest score)




The algorithm



The algorithm



Drugs used in third-line ART (adults)




DRV 400 mg is now available in SA


- Currently patients on DRV in third-line receive DRV/r 600/100 mg bid
- A small proportion of third-line patients have no DRV RAMs, and in such patients it may be possible to use DRV/r 800/100 mg daily instead of DRV/r 600/100 mg bid to, reducing pill burden, dosing frequency and side effects
- Patients initiating third-line ART: if DRV score (Stanford) is zero on all genotypes, may initiate DRV 800/100 mg daily
- Switching patients already on third-line: the patient's VL must be LDL, AND the DRV score (Stanford) MUST be zero on all genotypes the patient has had done



Initiating third-line ART




On DRV/r based third-line ART (600/100 mg bid)



Final thoughts

- Third-line applications have increased in a non-linear trajectory since 2013
- Quality of applications
- What impact will the introduction of dolutegravir-based regimens have on second- and third-line ART?




Acknowledgements



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Adult third-line ART update

Michelle
Moorhouse

28 Oct 2018

SAHCS Conference



University of the Witwatersrand

WITS RHI

